Vabysmo Is Bright Spot For Roche In Bumpy Q3
Anticipation Grows On Alzheimer’s Result
Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.
You may also be interested in...
The firm’s Tecentriq has bounced back from recent setbacks with a pivotal success in the adjuvant liver cancer setting.
The move marks the second time since last year that Roche has withdrawn a urothelial carcinoma indication after its confirmatory trial failed to show an overall survival benefit.
The Swiss major’s new bispecific antibody could challenge Eylea’s standard of care status in another ophthalmic indication, macular edema due to retinal vein occlusion, but the older rival is set to hit back in bigger markets with a high-dose reformulation.